Assembly Biosciences Doses First Two Participants in Phase 2 Study

The Phase 2 study will evaluate ABI-6250’s safety, pharmacokinetics and antiviral activity in participants with chronic HDV infection. Initial data are expected in the fourth quarter of 2027.